Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
1.
Biochem Pharmacol ; : 116298, 2024 May 21.
Article in English | MEDLINE | ID: mdl-38782077

ABSTRACT

The intricate balance between excitation and inhibition (E/I) in the brain plays a crucial role in normative information processing. Dysfunctions in the E/I balance have been implicated in various psychiatric disorders, including schizophrenia (SCZ). In particular, abnormalities in GABAergic signaling, specifically in parvalbumin (PV)-containing interneurons, have been consistently observed in SCZ pathophysiology. PV interneuron function is vital for maintaining an ideal E/I balance, and alterations in PV interneuron-mediated inhibition contribute to circuit deficits observed in SCZ, including hippocampus hyperactivity and midbrain dopamine system overdrive. While current antipsychotic medications primarily target D2 dopamine receptors and are effective primarily in treating positive symptoms, novel therapeutic strategies aiming to restore the E/I balance could potentially mitigate not only positive symptoms but also negative symptoms and cognitive deficits. This could involve, for instance, increasing the inhibitory drive onto excitatory neurons or decreasing the putative enhanced pyramidal neuron activity due to functional loss of PV interneurons. Compounds targeting the glycine site at glutamate NMDA receptors and muscarinic acetylcholine receptors on PV interneurons that can increase PV interneuron drive, as well as drugs that increase the postsynaptic action of GABA, such as positive allosteric modulators of α5-GABA-A receptors, and decrease glutamatergic output, such as mGluR2/3 agonists, represent promising approaches. Preventive strategies aiming at E/I balance also represent a path to reduce the risk of transitioning to SCZ in high-risk individuals. Therefore, compounds with novel mechanisms targeting E/I balance provide optimism for more effective and tailored interventions in the management of SCZ.

2.
Basic Clin Pharmacol Toxicol ; 134(5): 614-628, 2024 May.
Article in English | MEDLINE | ID: mdl-38426366

ABSTRACT

The brain extracellular matrix (ECM) has garnered increasing attention as a fundamental component of brain function in a predominantly "neuron-centric" paradigm. Particularly, the perineuronal nets (PNNs), a specialized net-like structure formed by ECM aggregates, play significant roles in brain development and physiology. PNNs enwrap synaptic junctions in various brain regions, precisely balancing new synaptic formation and long-term stabilization, and are highly dynamic entities that change in response to environmental stimuli, especially during the neurodevelopmental period. They are found mainly surrounding parvalbumin (PV)-expressing GABAergic interneurons, being proposed to promote PV interneuron maturation and protect them against oxidative stress and neurotoxic agents. This structural and functional proximity underscores the crucial role of PNNs in modulating PV interneuron function, which is critical for the excitatory/inhibitory balance and, consequently, higher-level behaviours. This review delves into the molecular underpinnings governing PNNs formation and degradation, elucidating their functional interactions with PV interneurons. In the broader physiological context and brain-related disorders, we also explore their intricate relationship with other molecules, such as reactive oxygen species and metalloproteinases, as well as glial cells. Additionally, we discuss potential therapeutic strategies for modulating PNNs in brain disorders.


Subject(s)
Interneurons , Parvalbumins , Parvalbumins/metabolism , Interneurons/metabolism , Extracellular Matrix/metabolism , Neurons/metabolism , Brain/metabolism
3.
Article in English | MEDLINE | ID: mdl-37535820

ABSTRACT

Background: The concept of an "entourage" effect in the cannabis and cannabinoids' field was first introduced in the late 1990s, during a period when most research on medical cannabinoids focused on the effects of isolated cannabinoids, such as cannabidiol and Δ9-tetrahydrocannabinol. Over the past decade, however, with the increased understanding of the endocannabinoid system, the discovery of other phytocannabinoids and their potential therapeutic uses, the term has gained widespread use in scientific reviews and marketing campaigns. Objective: Critically review the application of the term "entourage effect (EE)" in the literature and its endorsement by certain sectors of the cannabis market. Also, explore the perspectives for further interpretation and elaboration of the term based on current evidence, aiming to contribute to a more nuanced understanding of the concept and its implications for cannabinoid-based medicine. Methods: A comprehensive review of the literature was conducted to evaluate the current state of knowledge regarding the entourage effect. Relevant studies and scientific reviews were analyzed to assess the evidence of clinical efficacy and safety, as well as the regulation of cannabinoid-containing product production. Results: The EE is now recognized as a synergistic phenomenon in which multiple components of cannabis interact to modulate the therapeutic actions of the plant. However, the literature provides limited evidence to support it as a stable and predictable phenomenon. Hence, there is also limited evidence to support clinical efficacy, safety, and appropriate regulation for cannabinoid-containing products based on a "entourage" hypothesis. Conclusion: The EE has significant implications for the medical use of cannabinoid-containing products and their prescription. Nevertheless, a critical evaluation of the term's application is necessary. Further research and evidence are needed to establish the clinical efficacy, safety, and regulatory framework for these products. It's crucial that regulators, the pharmaceutical industry, the media, and health care providers exercise caution and avoid prematurely promoting the entourage effect hypothesis as a scientific proven phenomenon for cannabinoids and other cannabis-derived compound combinations.

4.
Diagn. tratamento ; 24(4): [153-157], out - dez. 2019. fig, tab
Article in Portuguese | LILACS | ID: biblio-1049386

ABSTRACT

Contexto e objetivos: Aroeira é o nome popular de árvores da família Anacardiaceae, que inclui plantas sensibilizantes como a poison ivy norte-americana (Toxicodendron radicans), o cajueiro (Anacardium occidentale) e a mangueira (Mangifera indica). Este estudo procura caracterizar o conhecimento sobre as aroeiras e a frequência de manifestações clínicas em camponeses. Desenho e local: Foi realizado estudo retrospectivo e prospectivo com pacientes e acompanhantes residentes em ampla área rural de cerrado no Centro-Oeste paulista. Métodos: A frequência e a relação causal entre a exposição a aroeiras, comuns na região, e a dermatite eczematosa típica foi pesquisada. Para a avaliação, foi utilizado um questionário específico. Resultados: Todos os 39 entrevistados conheciam aroeiras (100%) e 17 deles (43,58%) relataram ter se aproximado ou descansado sob essas árvores. Mais da metade deles (56,41% ou 22 indivíduos) relataram dermatites que relacionaram às arvores. Os demais entrevistados não desenvolveram reações, mas conheciam pessoas que o fizeram (43,59%). Três pacientes, ou 7,69% da amostra, apresentavam lesões de padrão eczematoso, creditando-as ao contato com aroeiras-bravas (Lithraea molleoides). Discussão: Devido à alta frequência com que essas árvores são encontradas no campo (cerrado brasileiro) e aos dados obtidos, percebemos também uma alta frequência de sensibilização nas áreas rurais. Conclusões: É imperativo que as campanhas de orientação e alerta sejam desenvolvidas para aumentar a conscientização sobre riscos potenciais, de modo que o contato com essas árvores seja evitado, evitando condições alérgicas que podem ser tão extensas quanto graves.


Subject(s)
Public Health , Retrospective Studies , Anacardiaceae , Dermatitis, Contact , Toxicity , Hypersensitivity
SELECTION OF CITATIONS
SEARCH DETAIL
...